INDICATION

EVENITY® is indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy...Read More

The anabolic effect of EVENITY® wanes after 12 monthly doses of therapy. Therefore, the duration of EVENITY® use should be limited to 12 monthly doses. If osteoporosis therapy remains warranted, continued therapy with an antiresorptive agent should be considered. Close
For US Healthcare Professionals
Indication Prescribing Information Important Safety Information Patient Site Prolia® HCP Site CONNECT WITH A REP

You are now leaving EVENITYHCP.com

You are about to leave the EVENITYHCP.com website and enter a website operated by a third party. Amgen is not responsible for, and does not endorse or control, the content contained on this third-party website.

Cancel Continue

Medical benefit

100% of Medicare Part B patients have access to EVENITY® as initial therapy1,*

  • No step edit required
  • No prior authorization required

89% of Medicare Part B patients pay $0 for each dose of EVENITY®
(after meeting deductible)2,†,‡

  • After deductible has been met, Medicare typically picks up 80% of office-administered products under Part B3
  • Patients may obtain an additional insurance plan (eg, Medigap, commercial, TRICARE) to pick up the additional 20%4,§
  • Data do not include medical benefit out-of-pocket (OOP) costs related to office visits or administration of EVENITY®. Additional insurance may require additional monthly premiums. Individual OOP costs will vary

*All Medical Lives associated with Coverage Restriction for EVENITY® in MMIT Coverage data snapshot as of January 2025 are included in this analysis.1

†Amgen® SupportPlus insurance verification data for January 2024–December 2024 was analyzed to determine the OOP distribution. EVENITY® prospective patients are only included in the analysis.1

‡The co-pay amount may depend on coverage of additional insurance plan(s).

§Patients should be enrolled in Medicare Part A and Part B. Medicare patients with supplemental coverage (eg, Medigap) may require additional premiums.4

Amgen® SupportPlus logoAmgen® SupportPlus logo

Helping eligible commercially insured patients lower out-of-pocket costs

The Amgen SupportPlus Co-Pay Program can help eligible commercially insured patients lower their out-of-pocket prescription costs, including deductible, co-insurance, and co-payment.*

  • For EVENITY®, pay as little as $25 out-of-pocket for each dose
  • Can be applied to deductible, co-insurance, and co-payment*

Amgen® SupportPlus copay card

Help patients enroll online at amgensupportplus.com/copay or by phone at 1-866-264-2778

*Eligibility criteria and program maximums apply. See www.amgensupportplus.com/copay for full Terms and Conditions.

Co-Pay Enrollment Video

Watch a video on how to assist your eligible commercially insured patients in the
Amgen Co-Pay program

Amgen® SupportPlus

We’re right here, right when you need us. Personalized support that you and your patients can count on across Amgen therapies.

benefits-verification-iconBenefits verification

Amgen SupportPlus can verify patient’s insurance plan coverage details.

Visit MyAmgenPortal.com to register and submit forms online or fax completed Insurance Verification Form to 1-877-877-6542.

Download EVENITY® insurance verification form
financial-support-iconFinancial support

We know every patient has unique needs. And we’re here to provide financial support information and resources, regardless of their current financial situation or type of insurance they have.

Amgen SupportPlus Customer Portal

A tool for managing patient benefits verification and more. Submit, store, and retrieve benefit
verifications electronically.

Visit MyAmgenPortal.com to register and submit forms online.

Amgen Portal

Click “Resources” on the Amgen SupportPlus Customer Portal homepage and select EVENITY® in the drop-down menu (log-in credentials not required to access “Resources”)

Insurance Verification Request Video

Watch a video about submitting an insurance verification request through Amgen SupportPlus.

Prior Authorization Video

Watch a video on considerations for requesting a prior authorization.

cta-image cta-image

Call Amgen SupportPlus at 1-866-264-2778 Monday–Friday 9:00 am–8:00 pm ET.
Visit AmgenSupportPlus.com to learn how Amgen can help.

Amgen® Field Reimbursement Specialists

An Amgen Field Reimbursement Specialist can provide live or virtual coverage and access resources to support your patients.

Contact your Amgen Field Reimbursement Specialists for live or virtual support that includes:

fulfillment processesHelp with navigating prior authorization, appeals, and fulfillment processes
patient supportEducating on payer requirements and necessary documentation for individual patient support
Guidance on reimbursementGuidance on general reimbursement questions, including product coding and billing information

References: 1. Data on file, Amgen; [1]; 2025. 2. Data on file, Amgen; [2]; 2025. 3. Medicare.gov website. Medicare costs at a glance. https://www.medicare.gov/basics/costs/medicare-costs. Accessed February 10, 2025. 4. Medicare.gov website. What’s Medicare Supplement (Medigap)? https://www.medicare.gov/supplements-other-insurance/whats-medicare-supplement-insurance-Medigap. Accessed February 10, 2025.

IMPORTANT SAFETY INFORMATION FOR EVENITY®

POTENTIAL RISK OF MYOCARDIAL INFARCTION, STROKE, AND CARDIOVASCULAR DEATH

EVENITY® may increase the risk of myocardial infarction, stroke and cardiovascular death. EVENITY® should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. Consider whether the benefits outweigh the risks in patients with other cardiovascular risk factors. Monitor for signs and symptoms of myocardial infarction and stroke and instruct patients to seek prompt medical attention if symptoms occur. If a patient experiences a myocardial infarction or stroke during therapy, EVENITY® should be discontinued.

In a randomized controlled trial in postmenopausal women, there was a higher rate of major adverse cardiac events (MACE), a composite endpoint of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke, in patients treated with EVENITY® compared to those treated with alendronate.

Contraindications: EVENITY® is contraindicated in patients with hypocalcemia. Pre-existing hypocalcemia must be corrected prior to initiating therapy with EVENITY®. EVENITY® is contraindicated in patients with a history of systemic hypersensitivity to romosozumab or to any component of the product formulation. Reactions have included angioedema, erythema multiforme, and urticaria.

Hypersensitivity: Hypersensitivity reactions, including angioedema, erythema multiforme, dermatitis, rash, and urticaria have occurred in EVENITY®-treated patients. If an anaphylactic or other clinically significant allergic reaction occurs, initiate appropriate therapy and discontinue further use of EVENITY®.

Hypocalcemia: Hypocalcemia has occurred in patients receiving EVENITY®. Correct hypocalcemia prior to initiating EVENITY®. Monitor patients for signs and symptoms of hypocalcemia, particularly in patients with severe renal impairment or receiving dialysis. Adequately supplement patients with calcium and vitamin D while on EVENITY®.

Osteonecrosis of the Jaw (ONJ): ONJ, which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients receiving EVENITY®. A routine oral exam should be performed by the prescriber prior to initiation of EVENITY®. Concomitant administration of drugs associated with ONJ (chemotherapy, bisphosphonates, denosumab, angiogenesis inhibitors, and corticosteroids) may increase the risk of developing ONJ. Other risk factors for ONJ include cancer, radiotherapy, poor oral hygiene, pre-existing dental disease or infection, anemia, and coagulopathy.

For patients requiring invasive dental procedures, clinical judgment should guide the management plan of each patient. Patients who are suspected of having or who develop ONJ should receive care by a dentist or an oral surgeon. In these patients, dental surgery to treat ONJ may exacerbate the condition. Discontinuation of EVENITY® should be considered based on benefit-risk assessment.

Atypical Femoral Fractures: Atypical low-energy or low trauma fractures of the femoral shaft have been reported in patients receiving EVENITY®. Causality has not been established as these fractures also occur in osteoporotic patients who have not been treated.

During EVENITY® treatment, patients should be advised to report new or unusual thigh, hip, or groin pain. Any patient who presents with thigh or groin pain should be evaluated to rule out an incomplete femur fracture. Interruption of EVENITY® therapy should be considered based on benefit-risk assessment.

Adverse Reactions: The most common adverse reactions (≥ 5%) reported with EVENITY® were arthralgia and headache.

EVENITY® is a humanized monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity.

Please see EVENITY® full Prescribing Information, including Medication Guide.

IMPORTANT SAFETY INFORMATION FOR EVENITY®

POTENTIAL RISK OF MYOCARDIAL INFARCTION, STROKE, AND CARDIOVASCULAR DEATH

EVENITY® may increase the risk of myocardial infarction, stroke and cardiovascular death. EVENITY® should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. Consider whether the

Back to Top